Aim of this study is to evaluate in a population of osteoporotic chronic kidney disease patients the effect of denosumab:~on coronary calcification scores evolution (by multidetector computed tomography) after 24 months of follow-up~on abdominal aorta calcification scores evolution (by plain abdominal Xray) after 24 months of follow-up~on bone mineral density (femoral T-score) (by bone densitometry) at 24 months~on bone mineral density evolution (femoral T-score) (by bone densitometry) after 24 months of follow-up~on bone mineral density evolution (lumbar T-score) (by bone densitometry) after 24 months of follow-up~on parameters of bone remodelling after 24 months of follow-up~on cardiovascular morbidity (cardiovascular events) and mortality after 24 months of follow-up~the tolerance after 24 months of follow-up
Aim of this study is to evaluate in a population of osteoporotic chronic kidney disease patients the effect of denosumab:~on coronary artery calcification scores evolution after 24 months of followup~on abdominal aorta calcification scores evolution after 24 months of followup~on bone mineral density (femoral T-score) at 24 months~on bone mineral density evolution (femoral T-score) after 24 months of follow-up~on bone mineral density evolution (lumbar T-score) after 24 months of follow-up~on parameters of bone remodelling after 24 months of follow-up~on cardiovascular morbidity (cardiovascular events) and mortality after 24 months of follow-up~the tolerance after 24 months of follow-up